Cristina Bárcena

Cristina Bárcena

Auto-generated profile, based on publicly available information

Cristina Bárcena

Innate Immunity Group, Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Journal of Hepatology
Verified
Journal Article
Open access
CBCristina Bárcena
Cristina Bárcena
MSMilica Stefanovic
Milica Stefanovic
TATutusaus Anna
Tutusaus Anna
LJLeonel Joannas
Leonel Joannas
AMAnghara Menéndez
Anghara Menéndez
Albert MoralesAlbert Morales
Albert Morales
Liver fibrosis, an important health concern associated to chronic liver injury that provides a permissive environment for cancer development, is characterized by accumulation of extracellular matrix components mainly derived from activated hepatic stellate cells (HSCs). Axl, a receptor tyrosine kinase and its ligand Gas6, are involved in cell differentiation, immune response and carcinogenesis. HSCs were obtained from WT and Axl(-/-) mice, treated with recombinant Gas6 protein (rGas6), Axl siRNAs or the Axl inhibitor BGB324, and analyzed by western blot and real-time PCR. Experimental fibrosis was studied in CCl4-treated WT and Axl(-/-) mice, and in combination with Axl inhibitor. Gas6 and Axl serum levels were measured in alcoholic liver disease (ALD) and hepatitis C virus (HCV) patients. In primary mouse HSCs, Gas6 and Axl levels paralleled HSC activation. rGas6 phosphorylated Axl and AKT prior to HSC phenotypic changes, while Axl siRNA silencing reduced HSC activation. Moreover, BGB324 blocked Axl/AKT phosphorylation and diminished HSC activation. In addition, Axl(-/-) mice displayed decreased HSC activation in vitro and liver fibrogenesis after chronic damage by CCl4 administration. Similarly, BGB324 reduced collagen deposition and CCl4-induced liver fibrosis in mice. Importantly, Gas6 and Axl serum levels increased in ALD and HCV patients, inversely correlating with liver functionality. The Gas6/Axl axis is required for full HSC activation. Gas6 and Axl serum levels increase in parallel to chronic liver disease progression. Axl targeting may be a therapeutic strategy for liver fibrosis management.

20 August 2010 in Hepatology
Verified
Journal Article
Open access
PDF file
LLLaura Llacuna
Laura Llacuna
CBCristina Bárcena
Cristina Bárcena
LBLola Bellido-Martín
Lola Bellido-Martín
LFLaura Fernández
Laura Fernández
MSMilica Stefanovic
Milica Stefanovic
Albert MoralesAlbert Morales
Albert Morales
Growth arrest–specific gene 6 (GAS6) promotes growth and cell survival during tissue repair and development in different organs, including the liver. However, the specific role of GAS6 in liver ischemia/reperfusion (I/R) injury has not been previously addressed. Here we report an early increase in serum GAS6 levels after I/R exposure. Moreover, unlike wild-type (WT) mice, Gas6 −/− mice were highly sensitive to partial hepatic I/R, with 90% of the mice dying within 12 hours of reperfusion because of massive hepatocellular injury. I/R induced early hepatic protein kinase B (AKT) phosphorylation in WT mice but not in Gas6 −/− mice without significant changes in c-Jun N-terminal kinase phosphorylation or nuclear factor kappa B translocation, whereas hepatic interleukin-1β (IL-1β) and tumor necrosis factor (TNF) messenger RNA levels were higher in Gas6 −/− mice versus WT mice. In line with the in vivo data, in vitro studies indicated that GAS6 induced AKT phosphorylation in primary mouse hepatocytes and thus protected them from hypoxia-induced cell death, whereas GAS6 diminished lipopolysaccharide-induced cytokine expression (IL-1β and TNF) in murine macrophages. Finally, recombinant GAS6 treatment in vivo not only rescued GAS6 knockout mice from severe I/R-induced liver damage but also attenuated hepatic damage in WT mice after I/R. Conclusion: Our data have revealed GAS6 to be a new player in liver I/R injury that is emerging as a potential therapeutic target for reducing postischemic hepatic damage. (Hepatology 2010;)

20 February 2018 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
GAGemma Aran
Gemma Aran
LSLucia Sanjurjo
Lucia Sanjurjo
CBCristina Barcena
Cristina Barcena
MSMarina Simon‐Coma
Marina Simon‐Coma
ÉTÉrica Téllez
Érica Téllez
MSMaria-Rosa Sarrias
Maria-Rosa Sarrias
CD5‐like (CD5L) is a soluble scavenger cysteine‐rich protein that modulates inflammatory responses. We studied the involvement of CD5L in liver cancer. Immunohistochemistry (IHC) of CD5L in 60 hepatocellular carcinomas and 34 adjacent nontumor livers, showed that CD5L staining was higher in tumor than in nontumor tissue (Mann‐Whitney test; P = 0.0039). High CD5L correlated with elevated proliferation (Ki67, linear regression; P < 0.0001) and lower patient event‐free survival (log‐rank; P = 0.0185). Accordingly, CD5L expression was detected in the liver cancer cell lines Huh7, HepG2, and SNU‐398. In vitro technologies using these cell lines, including small interfering RNA (siRN A ) and cDNA transfection, showed that CD5L promoted colony formation and cell proliferation and protected against cisplatin‐induced apoptosis. To find a molecular explanation for these roles, novel CD5L‐interacting protein ligands in liver cancer cells were identified by immunoprecipitation followed by mass spectrometry. Among these, the molecular chaperone of the unfolded protein response (UPR), heat shock protein (HSP)‐A5, was selected for validation. The interaction was confirmed by confocal microscopy in the Huh7 and HepG2 cell lines. Furthermore, functional experiments revealed that CD5L activates the UPR and autophagy mechanisms in Huh7 cells, thereby providing a novel molecular link between the UPR and autophagy in liver cancer.—Aran, G., Sanjurjo, L., Barcena, C., Simon‐Coma, M., Tellez, E., Vazquez‐Vitali, M., Garrido, M., Guerra, L., Díaz, E., Ojanguren, I., Elortza, F., Planas, R., Sala, M., Armengol, C., Sarrias, M.‐R. CD5L is upregulated in hepatocellular carcinoma and promotes liver cancer cell proliferation and antiapoptotic responses by binding to HSPA5 (GRP78). FASEB J. 32, 3878–3891 (2018). www.fasebj.org

1 May 2019 in EBioMedicine
Verified
Journal Article
Open access
CBCristina Bárcena
Cristina Bárcena
GAGemma Aran
Gemma Aran
LPLuís Perea
Luís Perea
LSLucia Sanjurjo
Lucia Sanjurjo
ÉTÉrica Téllez
Érica Téllez
MSMaria-Rosa Sarrias
Maria-Rosa Sarrias
Chronic hepatic inflammation leads to liver fibrosis, which may progress to cirrhosis, a condition with high morbidity. Our aim was to assess the as yet unknown role of innate immunity protein CD5L in liver fibrosis. CD5L was measured by ELISA in plasma samples from cirrhotic (n = 63) and hepatitis (n = 39) patients, and healthy controls (n = 7), by immunohistochemistry in cirrhotic tissue (n = 12), and by quantitative RT-PCR in mouse liver cell subsets isolated by cell sorting. Recombinant CD5L (rCD5L) was administered into a murine model of CCl4-induced fibrosis, and damage, fibrosis and hepatic immune cell infiltration, including the LyC6hi (pro-fibrotic)-LyC6low (pro-resolutive) monocyte ratio were determined. Moreover, rCD5L was added into primary human hepatic stellate cells to study transforming growth factor β (TGFβ) activation responses. Cirrhotic patients showed elevated plasma CD5L concentrations as compared to patients with hepatitis and healthy controls (Mann-Whitney test p < 0·0001). Moreover, plasma CD5L correlated with disease progression, FIB4 fibrosis score (r:0·25, p < 0·0001) and tissue expression (r = 0·649; p = 0·022). Accordingly, CCl4-induced damage increased CD5L levels in total liver, particularly in hepatocytes and macrophages. rCD5L administration attenuated CCl4-induced injury and fibrosis as determined by reduced serum transaminase and collagen content. Moreover, rCD5L inhibited immune cell infiltration and promoted a phenotypic shift in monocytes from LyC6hi to LyC6low. Interestingly, rCD5L also had a direct effect on primary human hepatic stellate cells promoting SMAD7 expression, thus repressing TGFβ signalling. Our study identifies CD5L as a key pleiotropic inhibitor of chronic liver injury. FUND: Fundació Marató TV3, AGAUR and the ISCIII-EDRF.

21 January 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CBCristina Bárcena
Cristina Bárcena
MSMilica Stefanovic
Milica Stefanovic
TATutusaus Anna
Tutusaus Anna
GMGuillermo A. Martinez-Nieto
Guillermo A. Martinez-Nieto
LGLaura Martinez Gili
Laura Martinez Gili
Albert MoralesAlbert Morales
Albert Morales
Hepatocellular carcinoma (HCC) frequently develops in a pro-inflammatory and pro-fibrogenic environment with hepatic stellate cells (HSCs) remodeling the extracellular matrix composition. Molecules secreted by liver tumors contributing to HSC activation and peritumoral stromal transformation remain to be fully identified. Here we show that conditioned medium from HCC cell lines, Hep3B and HepG2, induced primary mouse HSCs transdifferentiation, characterized by profibrotic properties and collagen modification, with similar results seen in the human HSC cell line LX2. Moreover, tumor growth was enhanced by coinjection of HepG2/LX2 cells in a xenograft murine model, supporting a HCC-HSC crosstalk in liver tumor progression. Protein microarray secretome analyses revealed angiogenin as the most robust and selective protein released by HCC compared to LX2 secreted molecules. In fact, recombinant angiogenin induced in vitro HSC activation requiring its nuclear translocation and rRNA transcriptional stimulation. Moreover, angiogenin antagonism by blocking antibodies or angiogenin inhibitor neomycin decreased in vitro HSC activation by conditioned media or recombinant angiogenin. Finally, neomycin administration reduced tumor growth of HepG2-LX2 cells coinjected in mice. In conclusion, angiogenin secretion by HCCs favors tumor development by inducing HSC activation and ECM remodeling. These findings indicate that targeting angiogenin signaling may be of potential relevance in HCC management.

22 January 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
MSMilica Stefanovic
Milica Stefanovic
TATutusaus Anna
Tutusaus Anna
GMGuillermo A. Martinez-Nieto
Guillermo A. Martinez-Nieto
CBCristina Bárcena
Cristina Bárcena
EGEstefania de Gregorio
Estefania de Gregorio
Albert MoralesAlbert Morales
Albert Morales
Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma